A Phase 1b Study to Assess the Safety Profile, Pharmacokinetics, and Anti-VEGF Activity of PTC299 in Patients With Advanced Cancer.
Phase of Trial: Phase I
Latest Information Update: 06 Apr 2012
At a glance
- Drugs Docetaxel; PTC 299
- Indications Cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors PTC Therapeutics
- 06 Apr 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 27 May 2010 Planned number of patients changed from 42 to 76 as reported by ClinicalTrials.gov.
- 27 May 2010 Planned end date changed from 1 Jun 2010 to 1 Jun 2014 as reported by ClinicalTrials.gov.